Alto Ingredients Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Alto Ingredients şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
n/a
Geri Alım Getirisi
| Toplam Hissedar Getirisi | n/a |
| Gelecekteki Temettü Verimi | n/a |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.
Anlatı Güncellemesi • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Anlatı Güncellemesi • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Anlatı Güncellemesi • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Anlatı Güncellemesi • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Anlatı Güncellemesi • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Anlatı Güncellemesi • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Anlatı Güncellemesi • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Anlatı Güncellemesi • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Anlatı Güncellemesi • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Analiz Makalesi • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Anlatı Güncellemesi • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Analiz Makalesi • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Analiz Makalesi • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Yeni Anlatı • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Analiz Makalesi • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analiz Makalesi • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Analiz Makalesi • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analiz Makalesi • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 19
Alto Ingredients: The Decline Has Created A Buying Opportunity
Summary Alto Ingredients has experienced some downward pressure over the past few months, even in spite of growing revenue and profits. Some of the bottom-line figures are deceptive given the role that a grant played in the matter, but the overall picture is still improving. Risk appears fairly low and shares look attractively priced right now. Just because an investment didn't offer attractive prospects at one point in time doesn't mean that the picture can't change for the better. As strong performance continues to be demonstrated and as shares of a company decline in price, the attractiveness of the firm in question can become more appealing, eventually reaching the point that assigning it a ‘buy’ rating just makes sense. One example of this can be seen by looking at Alto Ingredients (ALTO), a firm that produces and markets specialty alcohols and other essential ingredients for its customers. Recently, shares of the company have fallen even as fundamental performance remains strong. In addition to shares getting cheaper, the company continues to have cash in excess of debt totaling $22.2 million, leaving it with a good amount of wiggle room should market conditions worsen. Long term, investors should still expect significant volatility from a fundamental perspective. But given where shares are priced today, I do feel comfortable increasing my rating on the firm from a ‘hold’ to a ‘buy’, reflecting my opinion that the company’s stock should outperform the broader market for the foreseeable future. Robust strength changed my opinion Back in July of this year, I wrote an article that looked upon Alto Ingredients in a very neutral way. In truth, I was turned off by the volatility the company had seen in prior years, especially when it came to profitability. Having said that, profits in 2020 and 2021 proved to be rather robust for the company thanks to the change in market conditions. These changes, combined with a refusal by the market to push shares higher, leads into the stock looking rather cheap. But I still couldn't get over the company's business model and volatility as risk factors, ultimately resulting in a ‘hold’ rating for the business. Since then, shares of the firm have performed slightly better than I would have anticipated. While the S&P 500 has dropped by 12.9%, Alto Ingredients has seen a drop of 9.8%. Author - SEC EDGAR Data This return disparity is not necessarily large enough to be anything more than statistical noise. Having said that, it is also true that the company has continued to generate strong fundamental growth during this window of time. To see what I mean, we need only look at results covering the second quarter of the company's 2022 fiscal year. This is the only quarter for which data is now available that was not available when I last wrote about it. During that quarter, revenue came in at $362.2 million. That's 21.5% higher than the $298.1 million generated the same quarter only one year earlier. Total gallons of specialty alcohols the company sold actually dropped, declining from 125 million to 107.1 million. However, the firm did benefit from an increase in average pricing per gallon from $2.41 to $2.84. This drop in gallons sold was largely driven by a reduction in 3rd party gallons as the company continued to focus on the marketing and sales efforts associated with its own core production assets. The company also saw a more than doubling of sales of alcohol from its other production segment, driven by a rise in gallons sold of 14.4 million. This represents a 176% rise year over year. That unit also benefited from a $0.27 per gallon increase year over year. Meanwhile, essential ingredients revenue jumped by 221% to $23.4 million, driven by a 140% rise in volume and a 34% increase in average sales price per ton. Author - SEC EDGAR Data Clearly, the company's growth initiatives, particularly with regard to its emphasis on its own core production and to expanding into the specialty alcohols and essential ingredients spaces have proven to be beneficial for shareholders. The end result has also been an improvement in profitability. Net income in the second quarter of this year totaled $22.1 million. That's significantly higher than the $8.4 million reported one year earlier. Operating cash flow rose from $8.5 million to $9.6 million. But if we adjust for changes in working capital, the picture would have been even better, with the metric growing from $24.2 million to $38.4 million. Meanwhile, EBITDA also improved, rising from $17 million to $29.9 million. It is worth mentioning that profitability for the company was somewhat skewed. Although revenue has been rising, the firm benefited to the tune of $22.7 million from a grant associated with the USDA. Without that, operating income would have actually declined from $6.1 million in the second quarter of 2021 to negative $0.15 million the same time this year. It is worth mentioning that total results for the first half of the year did also come in stronger than what the company achieved in the first half of 2021. This much can be seen in the chart above. Author - SEC EDGAR Data Unfortunately, we don't really know what to expect for the rest of the current fiscal year. Given the one-time nature of the grant I mentioned, it's difficult to know what the organic potential the firm is. So instead of projecting out what results might look like for the rest of the year, I decided to price the company using data from 2021. Using this approach, the firm is trading at a price to adjusted operating cash flow multiple of 6.9 and at an EV to EBITDA multiple of 3.4. As part of my analysis, I compared the company to two other firms that are somewhat similar in nature. On a price to operating cash flow basis, these companies traded at multiples of 1.5 and 15.3. And using the EV to EBITDA approach, the multiples were 0.6 and 6.3. In both cases, our prospect was in the middle of the two.Seeking Alpha • Sep 12
Alto Ingredients gains on announcing $50M share repurchase program
Alto Ingredients (NASDAQ:ALTO) climbs on 4.76% premarket on authorizing share repurchase program for up to $ 50M of its common stock with an initial purchase authorization of $10M. “Given our positive long-term outlook, we believe our shares are currently undervalued. Based on the strength of our balance sheet, an opportunity exists to create value for our stockholders by repurchasing stock while we continue to upgrade our equipment and operating systems to increase efficiency and plant reliability, expand our corn storage capacity, enhance our specialty alcohol production, broaden our distribution, and reinvest in essential ingredients capabilities,” said Michael Kandris, CEO of Alto Ingredients.Analiz Makalesi • Aug 31
Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: ALTO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: ALTO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Alto Ingredients Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (ALTO) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.3% |
| Sektör Ortalaması (Chemicals) | 1.7% |
| Analist tahmini (ALTO) (3 yıla kadar) | n/a |
Önemli Temettü: ALTO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ALTO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: ALTO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: ALTO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 11:50 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Alto Ingredients, Inc. 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |